Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis by Chamian, Francesca et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Journal of Translational Medicine
Open Access Research
Alefacept (anti-CD2) causes a selective reduction in circulating 
effector memory T cells (Tem) and relative preservation of central 
memory T cells (Tcm) in psoriasis
Francesca Chamian, Shao-Lee Lin, Edmund Lee, Toyoko Kikuchi, 
Patricia Gilleaudeau, Mary Sullivan-Whalen, Irma Cardinale, 
Artemis Khatcherian, Inna Novitskaya, Knut M Wittkowski, 
James G Krueger* and Michelle A Lowes
Address: Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA
Email: Francesca Chamian - mfnchamian@msn.com; Shao-Lee Lin - shaol@amgen.com; Edmund Lee - elee96@yahoo.com; 
Toyoko Kikuchi - kikuchi@rockefeller.edu; Patricia Gilleaudeau - gilleap@rockefeller.edu; Mary Sullivan-Whalen - whalems@rockefeller.edu; 
Irma Cardinale - cardini@rockefeller.edu; Artemis Khatcherian - khatcha@rockefeller.edu; Inna Novitskaya - novitsi@rockefeller.edu; 
Knut M Wittkowski - kmw@rockefeller.edu; James G Krueger* - jgk@rockefeller.edu; Michelle A Lowes - lowesm@rockefeller.edu
* Corresponding author    
Abstract
Background: Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells
(Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.
Methods: Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to
severe psoriasis.
Results: In all patients, this treatment caused a preferential decrease in effector memory T cells
(CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T
cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were
relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-γ-producing) were also
significantly reduced.
Conclusion: Alefacept causes a selective reduction in circulating effector memory T cells (Tem)
and relative preservation of central memory T cells (Tcm) in psoriasis.
Background
A major pathogenic hypothesis for psoriasis vulgaris is
that it is an inflammatory autoimmune disease initiated
and sustained in skin regions through the actions of mem-
ory CD4+ and CD8+ T lymphocytes that serve as Type 1
effectors [1,2]. A significant expansion of Type 1 T cells in
the peripheral circulation of psoriasis patients has been
measured [3]. A number of biological therapies have been
recently approved for use in psoriasis, such as Alefacept
(lymphocyte function-associated antigen [LFA]-3 T cell
inhibitory protein [TIP]; anti-CD2; Amevive; Biogen
Idec), which is effective in approximately 30% of psoriasis
patients (75% clinical response from baseline) [4].
Understanding the effects and actions of such an agent is
useful to evaluate the relative contribution of different cell
types to the pathogenesis of psoriasis.
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CD2 is a costimulatory molecule found predominantly
on lymphocytes and natural killer (NK) cells [5], but also
on a small subset of dendritic cells (DCs) [6,7]. CD2 bind-
ing regulates the threshold of antigen to which T cells will
react, increasing the affinity of the immune synapse, and
it is important for effector actions of differentiated CD8+
cytotoxic T lymphocytes [5,8]. CD2 ligation can deliver a
stimulatory or inhibitory signal, or be involved in lym-
phocyte adhesion, depending on the system studied [9-
12].
Alefacept is a fusion protein combining the first extracel-
lular domain of LFA3 (CD58) with constant regions (CH2
and CH3) and the hinge domain of human IgG1. Ale-
facept has a number of effects in vitro including decreas-
ing T cell alloreactivity and stimulating NK-mediated lysis
of target cells. The proposed mechanism of action of ale-
facept is to bridge lymphocytes and NK cells by binding to
CD2 and FcRIII, respectively [4,13,14]. Theoretically, this
activates the NK cell to release its cytotoxic granules lead-
ing to lymphocyte apoptosis. However, these in vitro
experiments used significantly higher doses of alefacept
than were used in subsequent clinical trials, and also non-
physiological doses of NK: T cells, so it is difficult to estab-
lish their relevance to in vivo mechanisms of action.
Recently, several groups have further classified memory T
cell subpopulations (CD45RO+ or CD45RA-), describing
cells by correlating surface phenotype and function
[15,16]. Central memory T cells (Tcm) are CCR7+, express
additional lymph-node homing receptors, lack immedi-
ate effector function, and differentiate into CCR7- cells on
secondary stimulation. Effector memory T cells (Tem) are
CCR7-, demonstrate receptors for inflamed tissue, and are
capable of immediate effector function. Effector CD8+ T
cells can be further defined as CD45RA+ CD27- and CD28-
[17]. These cells secrete interferon (IFN)-γ and tumor
necrosis factor (TNF)-α, require exogenous cytokines for
proliferation such as IL-2 and IL-15, and have cytolytic
function.
We applied this more specific classification system to eval-
uate the relative T cell reduction caused by alefacept treat-
ment. Studies to date have shown that there is a dose
dependant reduction in circulating CD4+  and CD8+
CD45RO+ memory T cells [4], which remained reduced
with a second course of alefacept [18]. We found that
CD4+ and CD8+ effector memory T cells (Tem) (CCR7-
CD45RA-) were significantly decreased, with relatively less
effect on central memory T cells (Tcm) (CCR7+ CD45RA-)
and naïve T cells (CCR7+CD45RA+). There were also
reductions in circulating CD8+ effector T cells (CCR7-
CD45RA+) and type 1 T cells (IFN-γ producing T cells).
The relative preservation of naïve and central memory T
cells is an important finding of this study.
Methods
Study design
Twenty-two patients with moderate to severe psoriasis (19
males, 3 females, ages 29–68 years, median 49 years) were
enrolled in this study, which was approved by The Rock-
efeller University Hospital Institutional Review Board,
and completed in 2003. Informed consent was obtained.
This group of patients has been described previously [19].
Major inclusion criteria were: involvement of psoriasis
vulgaris of >10% body surface area, no treatment for at
least 4 weeks prior to entering the study, no significant
infections nor immunosuppression, and no significant
renal, hepatic or other medical disease. Patients were
treated with twelve 7.5 mg weekly intravenous doses of
alefacept, and the effect of this fusion protein on circulat-
ing T cells was studied by fluorescence-activated cell sort-
ing (FACS). Two patients withdrew due to non-response
and did not have final blood draws or biopsies.
Peripheral blood and skin samples
Peripheral blood draws were taken at 0, 1, 6 and 24 hours,
and weeks 2, 4 and 13, before drug administration. Neu-
trophil, lymphocyte and monocyte counts were deter-
mined by routine complete blood count. Peripheral
blood mononuclear cells (PBMCs) were isolated from
heparinized samples using standard Ficoll-Hypaque
(Pharmacia Biotech Inc., Piscataway, New Jersey) density
gradient sedimentation. PBMCs were frozen in 10%
dimethylsulfoxide (DMSO; ATCC, Manassas, Vermont) in
RPMI-1640 (Gibco-BRL Life Technologies, Rockville,
Maryland) with 1 mM HEPES buffer (Sigma Aldrich, St.
Louis, Missouri), 0.1% gentamicin (Gibco-BRL Life Tech-
nologies) and 5% normal human serum (C-Six Diagnos-
tics, Germantown, Wisconsin), and stored at -80°C until
required. Skin punch biopsies were obtained at baseline
(nonlesional and lesional), 2, 6 and 13 weeks (lesional).
Tissue was frozen in OCT compound (Sakura Finetechni-
cal, Tokyo, Japan) and stored at -80°C for immunohisto-
chemistry, and liquid nitrogen for RNA extraction.
Histologic response (remission) of psoriatic lesions was
defined by normalization of keratin 16 expression (nega-
tive in normal epidermis) in week 13 biopsies and marked
reduction in epidermal hyperplasia (quantified by com-
puter- assisted image analysis) [19]. Change in epidermal
thickness was calculated as a percentage by the following
formula [(epidermal thickness at week 13 - epidermal
thickness at week 0)/epidermal thickness at week 0] ×
100. Other cases showed a range of outcomes that varied
from some reduction in epidermal hyperplasia (but sus-
tained keratin 16 expression) to no improvement in
hyperplasia. These cases are termed "nonresponders".Journal of Translational Medicine 2007, 5:27 http://www.translational-medicine.com/content/5/1/27
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Peripheral blood mononuclear cell phenotype
PBMCs were stained for 15 minutes at room temperature
with the following antibodies (5 µl/105  cells): CD2,
CD19, CD45RA (fluorescein isothiocyanate, FITC), CD8,
CD16, CD27, CD45RO, CD49d, CD56 (phycoerythrin,
PE), CD3, CD4, CD8 (peridinin-chlorophyll-protein,
PerCP), CD3, CD45RO (allophycocyanin, APC) (Becton
Dickinson), CD11a (FITC) (Immunotech, Westbrook,
Maine), CD103 (FITC) (Biodesign International), cutane-
ous lymphocyte antigen (CLA/HECA) (FITC) (BD
Pharmingen), LFA-3TIP (PE) (BD Pharmingen, custom
design), CCR7 (PE) (R & D System, Minnesota). Appro-
priate IgG isotype controls were also used (Becton Dickin-
son). Cells were washed with FACSwash [0.1% sodium
azide (Sigma Aldrich), 2% fetal calf serum (Gibco-BRL
Life Technologies) in phosphate buffered saline] and
resuspended in 1.3% formaldehyde (Fisher Scientific) in
FACSwash. Samples were analyzed within 24 hours with
four color staining using a FACSCalibur Flow Cytometer
and CELLQuest software after calibration with CaliBRITE
beads and FacsComp sotware (Becton Dickinson).
Whole blood intracellular cytokine staining
Heparinized whole blood was activated for 4 hours using
25 ng/ml phorbol myristate acetate (PMA) and 2 µg/ml
ionomycin, in the presence of 10 µg/ml brefeldin A
(Sigma Aldrich Corp, St. Louis). Ethylenediaminetetraace-
tic acid was added (2 mM, Fisher). Red blood cells were
lysed using FACS Lysing solution (Becton Dickinson),
cells were washed and frozen in the media described
above (10% DMSO, 5% PHS in RPMI). Unactivated con-
trol cells were included in the assays. Prior to cytokine
staining, cells were thawed, washed and permeabilized
using FACS Permeabilizing solution (Becton Dickinson).
FACS analysis was performed using antibodies specific for
intracellular IFN-γ, IL-2 (FITC), TNF-α, IL-4 (PE) (Becton
Dickinson) and IL-10 (PE) (BD Pharmingen).
T cell activation (CD69 expression)
PBMCs were activated in vitro using 1 µg/ml OKT3 (anti-
CD3) (Ortho Biotech, Toronto, Canada) or 1 µg/ml T11.1
and T11.2 (anti-CD2) (Immunotech) for 4 hours. Early T
cell (CD3-FITC) activation was measured by surface
expression of CD69 (FITC). Samples were analyzed by
FACS as described for PBMC phenotype.
Statistics
Data were transformed into logarithmic data due to the
biological variability of the data and to accommodate out-
liers, and so averages are presented as geometric means.
Change at week 13 was compared to baseline using a 2-
tailed, paired student's t test; significance was accepted as
P < 0.05.
Results
Analysis of histologic response of psoriasis to alefacept 
administration
The patients demonstrated better than expected clinical
response rates, with 45% (10/22) of patients achieving an
improvement of Psoriasis Activity and Severity Index
(PASI) greater than 70%, with a mean overall reduction in
PASI of 50%. After alefacept administration, 55% (12 of
22) of patients were judged to have disease remission by
histologic criteria (outlined in materials and methods),
and are termed "responders". The other 10 patients were
termed "non-responders".
Alefacept preferentially decreases circulating memory T 
cell subsets
There is a dramatic reduction of peripheral lymphocytes
(38% reduction) and monocytes (58% reduction) during
the first hour of Alefacept administration, with quick
recovery within days [20]. Monocytes returned to baseline
levels, but lymphocyte counts were reduced by 23% over
the subsequent 12 weeks. Table 1 lists the changes in var-
ious populations of circulating lymphocytes after 12
weeks of alefacept administration. T cells were the main
population of lymphocytes that showed a decrease in
absolute cell number, whereas only slight changes were
seen in B cells and NK cells.
A variety of different leukocyte markers were used to
quantify naïve T cell populations and memory T cell pop-
ulations, including specific populations of memory T cells
specialized for homing to skin/epithelium and inflamma-
tory sites (Table 1). Naïve populations of CD4+ and CD8+
T cells were affected to a comparatively small extent by
alefacept, whereas memory populations were mainly tar-
geted by this agent. For example, memory CD4+ T cells
were decreased by a mean of 40%, and CD8+ memory
cells were decreased by a mean of 65%. T cells that were
differentiated for skin homing (CLA+), epithelial homing
(CD103+) or for binding to vascular cell adhesion mole-
cule-1 or intercellular adhesion molecule-1 (CD49dhi and
LFA-1hi, respectively) were strongly affected by alefacept
in the peripheral circulation. These observations suggest
that cell populations which differentiate for homing to
peripheral tissues (effector memory T cells) might be
selectively targeted by alefacept in psoriasis patients.
While circulating CD4+  and CD8+  memory cells were
reduced in all patients, there was some correlation
between CD4+ and CD8+ Tcm lymphocyte subpopula-
tions and change in PASI (R = 0.54, and R = 0.47, respec-
tively).
Alefacept selectively targets circulating effector memory T 
cells (Tem)
Memory populations of CD4+ and CD8+ T lymphocytes
can be divided into T cell populations that home mainlyJournal of Translational Medicine 2007, 5:27 http://www.translational-medicine.com/content/5/1/27
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to lymph nodes, central memory T cells (Tcm), versus
effector memory T cells (Tem), which home mainly to
peripheral or inflammatory sites. The expression of CCR7
and CD45RA was used to classify CD4+ or CD8+ T cells as
naïve (CCR7+ CD45RA+), Tcm (CCR7+ CD45RA-) or Tem
(CCR7- CD45RA-) [15]. In CD4+ T cells, the Tem popula-
tion was consistently affected to a much larger extent than
the Tcm population (Table 1) (mean reductions com-
pared to baseline of 63%, p < 10-4 versus 27%, not signif-
icant). Similarly, Tem cells in the CD8+ population were
affected more than Tcm cells (mean reductions of 63%,
versus 47%, both p < 10-4). At week 13, the difference in
CD4+ Tcm versus Tem, as well as CD8+ Tcm versus Tem
was also significant, (P < 10-4; 0.005 respectively).
Alefacept selectively reduces circulating Type 1 T cells
Because there is an increase in circulating Type 1 T cells in
psoriasis patients [3], we measured the effect of alefacept
on circulating populations of Type 1 (IFN-γ-producing)
and Type 2 (IL-4-producing) T cells by flow cytometry
(Fig. 1). Ninety percent of T cells at baseline and week 13
could be successfully activated by PMA and inonmycin, as
judged by induction of CD69 (data not shown). Type 1 T
cells were consistently reduced after alefacept administra-
tion (mean reduction 59%, p < 0.0001). Consistent reduc-
tions in TNF-α-producing and IL-2 producing T cell
subsets were also measured, but the overall effect was
smaller than on IFN-γ-producing T cells. There was much
less intracellular cytokine expression in the Type 2
cytokines IL-4 and IL-10, so interpretation is less mean-
ingful. There was a 2% mean reduction for IL-4 (p = 0.94)
and 32.9% mean reduction of IL-10 (p = 0.03).
Alefacept does not affect expression of CD69 after 
activation of PBMCs
In vitro activation of PBMCs with OKT3 and anti-CD2
monoclonal antibodies T11.1 and T11.2 showed no sta-
tistically significant difference in activation as measured
by surface CD69 expression at week 13 compared to base-
line (Fig. 2).
Alefacept binding parallels CD2 expression on memory T 
cell populations
Table 1 shows average mean fluorescence intensity (MFI)
values for CD2 expression in naïve, Tcm and Tem popula-
tions, as determined from combined measures in all
Table 1: Phenotypic analysis of peripheral blood mononuclear cells during treatment with Alefacept.
Cell type Phenotypic marker D0 Wk 13 Percent 
change
P value
T cell CD3+ 1474 967 -34.0 <10-4
Memory T cell CD3+ CD45RA- 900 467 -48.0 <10-4
B cell CD19+ 211 198 -6.0 0.65
NK cell CD56+ CD16+ CD3- 125 130 4.0 0.78
Naïve CD4+ CD4+ CD45RA+ 247 236 -5.0 0.60
Memory CD4+ CD4+ CD45RO+ 484 290 -40.0 0.0005
Naïve CD8+ CD8+ CD27+ CD45RA+ 166 135 -19.0 0.025
Memory CD8+ CD8+ CD27+ CD45RA- 164 57 -65.0 <10-4
Effector CD8+ CD8+ CD27- CD45RA+ 21 14 -32.0 0.015
CD4+ CD25+ T cells CD4+ CD25+ 525 365 -30.0 0.0124
Skin-homing CD4+ CD4+ CLA+ 86 44 -49.0 0.0012
Skin-homing CD8+ CD8+ CLA+ 23 12 -48.0 0.009
Epithelial-homing CD8+ CD8+ CD103+ 17 5 -70.0 <10-4
VLA-4lo CD8+ CD49dlo 172 132 -23.0 0.002
VLA-4hi CD8+ CD49dhi 226 97 -57.0 <10-4
LFA-1lo CD8+ CD11alo 201 155 -23.0 0.018
LFA-1hi CD8+ CD11ahi 202 80 -61.0 <10-4
Memory T cell subsets Phenotypic marker D0 Wk 13 Percent 
change
P value CD2 MFI D0 CD2 MFI Wk 13 P value
Naïve CD4+ CD4+ CCR7+ CD45RA+ 216 220 2.0 0.88 90 88 0.49
Tcm CD4+ CD4+ CCR7+ CD45RA- 377 274 -27.0 0.0135 141 119 0.0002
Tem CD4+ CD4+ CCR7- CD45RA- 179 67 -63.0 <10-4 198 146 <10-4
Naïve CD8+ CD8+ CCR7+ CD45RA+ 75 78 4.0 0.76 127 120 0.20
Tcm CD8+ CD8+ CCR7+ CD45RA- 48 25 -47.0 <10-4 192 159 0.003
Tem CD8+ CD8+ CCR7- CD45RA- 110 40 -63.0 <10-4 233 190 0.002
Effector CD8+ CD8+ CCR7- CD45RA+ 102 51 -50.0 0.0001 178 131 0.0002
Geometric mean absolute cell number per µl circulating blood at baseline (D0, day 0) and post treatment (week 13). Percent change is calculated 
by [(week 13-week 0)/week 0 as a %]. CD2 mean fluorescence intensity (MFI) of memory cell subsets. P value comparing week 0 and week 13.Journal of Translational Medicine 2007, 5:27 http://www.translational-medicine.com/content/5/1/27
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patients in the study. Tem populations tend to have
higher expression of CD2 compared to Tcm populations
and that slight (but statistically significant) reductions in
average CD2 MFI values were measured on memory cell
populations after alefacept administration. In overall
terms, levels of CD2 expression strongly parallels reduc-
tions in the respective cell populations in the peripheral
circulation after alefacept administration. This difference,
in turn, may be produced by quantitative differences in
alefacept binding to T cells.
Discussion
Alefacept is the first therapeutic agent targeted to T lym-
phocytes that has been shown to have a selective effect on
effector memory T cells (Tem) versus central memory T
cells (Tcm) in humans. Our results suggest that differen-
tial effects of alefacept on naïve versus Tcm and Tem T cell
pools relates to increased CD2 expression on effector T
cells (Table 1) and thus differential binding of alefacept to
surface CD2 molecules. The decreases in circulating pop-
ulations that are differentiated as Type 1 effectors (LFA-
1hi, VLA-4hi, αEβ7+, CLA+, and IFN-γ-producing T cells)
argue for roles of these T cell subsets in disease pathogen-
esis, and indeed these T cell subsets are concentrated in
skin lesions. Peripheral Type 1 deviation previously
observed in psoriasis [3] seems to be largely corrected
through alefacept administration, as Type 1 T cells are sig-
nificantly reduced at week 13, but Type 2 (IL-4 producing)
T cells are comparatively unaffected (Fig. 1).
An encouraging finding of this study is that central mem-
ory T cells (Tcm) and naïve T cells are relatively preserved.
This may be beneficial as there is realistic concern about
toxicity caused by T cell-targeted immunosuppressives,
particularly in the ability to sustain immunologic memory
and to mount immune responses to new pathogens.
Recall responses to intradermal antigens are preserved, as
are antibody responses to a neoantigen (phiX174) [21].
Although it is not yet clear which cells are actually most
important for maintaining immunological memory, it is
logical that maintenance of the naïve and central memory
populations should leave primary and recall responses
intact. Also, the changes in lymphocyte population with
Alefacept are opposite to those occurring in aging individ-
uals (immune senescence) where naïve T cells are
decreased and memory populations are increased [22].
T cells can still be activated during treatment with Alefacept Figure 2
T cells can still be activated during treatment with 
Alefacept. Percent CD69 positive cells following in vitro 
activation with control, anti-CD3 (OKT3) or anti-CD2 
(T11.1 and T11.2). Comparison of CD69 expression on T 
cells activated with either OKT3 or T11.1 and T11.2 at base-
line and week 13. No significant differences. Geometric mean 
data, standard error of the mean.
Type 1 T cells (IFN-γ producing) are decreased with ale- facept therapy Figure 1
Type 1 T cells (IFN-γ producing) are decreased with 
alefacept therapy. Intracellular cytokine FACS detection of 
mean number of TNF-α, IL-2 and IFN-γ cells/ml, which are 
significantly decreased with therapy, P value indicated.Journal of Translational Medicine 2007, 5:27 http://www.translational-medicine.com/content/5/1/27
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Although there is a consistent reduction in circulating
memory T cells in all patients, it is puzzling that there is
not a better correlation between clinical response and cir-
culating memory cell reductions; that is, everyone has a
relative reduction in T cells, but not everyone gets better.
The correlation coefficients for change in PASI and mem-
ory CD4 (CD45RO+) and CD8+ T cells (CD45RA-) are
similar to previously reported studies [4]. It is likely for
clinical and histological response, changes at the tissue
level are more important than those in the circulation. In
lesional psoriatic tissue, response to alefacept therapy cor-
relates extremely well with reductions in infiltrating lym-
phocytes (r = 0.9), lesional DCs and inflammatory genes
[19].
CD2 targeted therapeutics have been successful at delay-
ing rejection of allogeneic organ transplants in model sys-
tems, but have been less successful at reversing ongoing
rejection reactions [23] and, generally, effects of these
agents to decrease T cell antigen reactivity is restricted to
the period of initial antigen exposure. It is interesting that
Alefacept is effective in certain psoriasis patients, which is
an established reaction. We examined the ability of T cells
to be activated before and after alefacept administration
through CD3 antibodies or by use of mitogenic CD2 anti-
body combinations. While slight decreases in T cell activa-
tion were seen at week 13 after CD3 and CD2 ligation,
cells remained quite activatable, which is distinctly differ-
ent from previous in vitro studies which observed anergic
effects of alefacept [9].
Thus, the mechanism of T cell reductions remains to be
established. Possible mechanisms of action include the
previously proposed bridging effect between T cells and
NK cells leading to direct lymphocyte cell death. While we
have not found any evidence of apoptosis in the circula-
tion (data not shown), this may be occurring slowly at
least at the tissue level. Secondly, alefacept may preferen-
tially bind to lesional T cells, resulting in a disruption of
the organization of T cells and DCs in the tissue [2].
Thirdly, binding of alefacept to lymphocyte CD2 may
result in sequestration of the bound cell from the circula-
tion into lymphoid organs, and subsequent depletion. A
fourth possibility is that there is a relative increase in tis-
sue regulatory T cells.
Conclusion
This study is a detailed analysis of the effects of alefacept
on the circulating subpopulations of lymphocytes, and
the relative preservation of the naïve and central memory
T cells is an important finding. There are also reductions
in the putative pathogenic populations in psoriasis, Tem
and type 1 T cells.
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